Functional Mechanism(s) of the Inhibition of Disease Progression by Combination Treatment with Fingolimod Plus Pathogenic Antigen in a Glucose-6-phosphate Isomerase Peptide-Induced Arthritis Mouse Model

Biol Pharm Bull. 2015;38(8):1120-5. doi: 10.1248/bpb.b14-00873. Epub 2015 May 20.

Abstract

We previously reported that combination treatment with fingolimod (FTY720) plus antigenic peptide of glucose-6-phosphate isomerase (residues 325-339) (GPI325-339) from the onset of symptoms significantly inhibited disease progression in a mouse model of GPI325-339-induced arthritis. In this study, we investigated the mechanism(s) involved. The model mice were treated from arthritis onset with FTY720 alone, GPI325-339 alone, or the combination of FTY720 plus GPI325-339. At the end of treatment, inguinal lymph nodes (LNs) were excised and examined histologically and in flow cytometry. Levels of apoptotic cells, programmed death-1-expressing CD4(+)forkhead box P3(-) nonregulatory T cells (non-Tregs), and cytotoxic T-lymphocyte antigen 4-expressing non-Tregs in inguinal LNs were markedly increased in the combination treatment group mice. Regulatory T cells (Tregs) were also increased. These results indicate that combination treatment with FTY720 plus GPI325-339 inhibits the progression of arthritis by inducing clonal deletion and anergy of pathogenic T cells and also by immune suppression via Tregs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens* / immunology
  • Antigens* / pharmacology
  • Antigens* / therapeutic use
  • Arthritis, Experimental* / drug therapy
  • Arthritis, Experimental* / immunology
  • Arthritis, Rheumatoid* / drug therapy
  • Arthritis, Rheumatoid* / immunology
  • CD4-Positive T-Lymphocytes / metabolism
  • Combined Modality Therapy
  • Disease Models, Animal
  • Disease Progression
  • Fingolimod Hydrochloride / pharmacology*
  • Fingolimod Hydrochloride / therapeutic use
  • Glucose-6-Phosphate Isomerase* / immunology
  • Glucose-6-Phosphate Isomerase* / pharmacology
  • Glucose-6-Phosphate Isomerase* / therapeutic use
  • Immune Tolerance / drug effects*
  • Immunosuppressive Agents / pharmacology*
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Mice, Inbred DBA
  • Peptides / immunology
  • Peptides / pharmacology
  • Peptides / therapeutic use
  • T-Lymphocytes, Regulatory / metabolism

Substances

  • Antigens
  • Immunosuppressive Agents
  • Peptides
  • Glucose-6-Phosphate Isomerase
  • Fingolimod Hydrochloride